Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy

AIDS

Volumn 17, Issue 12, 2003, Pages 1855-1856

  Katlama, C ^a   Gazzard, B ^b   Mallolas, J ^c   Schurmann D ^d   Moroni, M ^e   Demonty, N ^f   Antoun, Z ^g   Gordon, D ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CHOLESTEROL; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC DISORDER; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; VIREMIA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0041731598     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200308150-00017     Document Type: Article

References (11)

1. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure and mortality:implications from a cohort of 361 662 men. Lancet 1986, ii:933-936.
2. Lafeuillade A TRIZAL: Comparison of the metabolic disorders and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART (AZL30002). In: 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece, 23-26 October 2001 [Poster and Oral Presentation 28].
3. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, et al. HIV PI substitution in patients with lipodystrophy: a randomised, controlled, open-label, multi-centre study. AIDS 2001, 15:1811-1822.
4. Clumeck N, Goebel F, Roznbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued PI based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001, 15:1517-1526.
5. Opravil M, Hirschel B, Lazzarin A, et al. A randomised trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodefiency virus infection. J Infect Dis 2002, 185:1251-1260.
6. Barreiro P, Soriano V, Blanco F, Casamiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV infected subjects under long-term successful triple combination therapy. AIDS 2000, 14:807-812.
7. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy:1-year prospective follow-up of a multi-centre, randomised, controlled study. J Acquit Immune Defic Syndr 2001, 27:229-236.
8. Becker S, Tachlis A, Gill J, et al. Successful substitution of protease inhibitors with efavirenz in patients with undetectable plasma HIV-1 RNA levels: results of a prospective, randomised, multi-center, open-label study (DMP 266-049). In: 5th International Congress on Drug Therapy in HIV Infection. [Abstract Nr.P.21.2002].
9. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long lasting suppression. Clin Infect Dis 2002, 34:504-510.
10. Martinez E, Podzamczer E, Ribera P, et al. Switching protease inhibitors to nevirapine (NEV), efavirenz (EFV), or abacavir (ABC): a randomised, multicentre, open-label, simplification trial. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 24-28 February 2002 [Abstract LB17 and Oral Presentation].
11. Moyle G, Baldwin C, Mandalia S, et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirvirenz in virologically controlled HIV-1-positive persons: single arm observational cohort. J Acquir Immune Defic Syndr 28:399-401.